Market Closed -
Australian S.E.
08:28:37 13/05/2024 am IST
5-day change
1st Jan Change
0.105
AUD
+5.00%
+5.00%
-58.00%
Presentation Operator MessageOperator (Operator)Thank you for standing by, and welcome to the ...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024
24/04
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
29/02
CI
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study
19/01
MT
Visioneering Technologies Issues Part of Shortfall from Rights Offering
05/01
MT
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
02/11
Transcript : Visioneering Technologies, Inc., Q3 2023 Earnings Call, Oct 18, 2023
19/23/19
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion
10/23/10
MT
Visioneering Technologies Appoints CEO
29/23/29
MT
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023
29/23/29
CI
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023
29/23/29
CI
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
17/23/17
CI
Transcript : Visioneering Technologies, Inc., Q2 2023 Earnings Call, Jul 21, 2023
21/23/21
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
25/23/25
Transcript : Visioneering Technologies, Inc., Q1 2023 Earnings Call, Apr 20, 2023
20/23/20
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal
13/23/13
MT
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
28/23/28
CI
Visioneering Technologies, Inc. Announces Board Changes
20/22/20
CI
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial
07/22/07
MT
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT
07/22/07
CI
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
27/22/27
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
23/22/23
CI
Transcript : Visioneering Technologies, Inc., Q2 2022 Earnings Call, Jul 20, 2022
21/22/21
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial
13/22/13
MT
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control
13/22/13
CI
Visioneering Technologies, Inc. Announces Board Changes
30/22/30
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Visioneering Technologies, Inc. is a medical device company. The Company is primarily engaged in the design, manufacture, sale and distribution of a contact lens, the NaturalVue Multifocal 1 Day (NaturalVue MF) contact lens. The Company operates through two segments: North America and Europe / Asia-Pacific. The North America segment includes its operations in the United States and Canada. The Europe/Asia-Pacific segment includes its operations outside of North America. Its flagship product is the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lens for adults with Presbyopia and children with Myopia. The Company sells its contact lenses in the United States, Europe, Australia, New Zealand, Hong Kong, Singapore, Canada and Malaysia. The Company manages the warehousing and distribution of its products through a contract with a third-party logistics provider (the 3PL).
More about the company
1st Jan change
Capi.
-58.00% 3.64M +13.71% 100B +13.07% 40.03B +0.16% 18.83B -14.13% 2.41B +4.89% 1.76B +24.59% 1.19B -34.19% 765M -34.01% 745M -6.50% 676M
Glasses, Spectacles & Contact Lenses
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1